Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CytoSorbentsSTU:HQE 45 9-Day RSI is 47.30 as of Sep. 11, 2026. GuruFocus rates STU:HQE with a GF Score™ of 45/100 and a GF Value™ of €16.19. The stock has 5 warning signs investors should review. Among 862 Medical Devices & Instruments companies, CytoSorbents ranks better than 57.08% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-09-11), CytoSorbents's 9-Day RSI is 47.30.
The industry rank for CytoSorbents's 9-Day RSI or its related term are showing as below:
STU:HQE's 9-Day RSI is ranked better than 57.08% of 862
companies
in the Medical Devices & Instruments industry
Industry Median: 41.145
vs STU:HQE: 47.30
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
CytoSorbents 9-Day RSI Related Terms
STU:HQE vs LFWD, GTHP, PMI: 9-Day RSI Comparison
For the Medical Devices subindustry, CytoSorbents's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytoSorbents 9-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CytoSorbents's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where CytoSorbents's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytoSorbents (STU:HQE) has a 9-Day RSI of 47.30 as of Sep. 11, 2026. According to the industry distribution chart, CytoSorbents ranks #370 out of 862 companies in the Medical Devices & Instruments industry, placing it in the top 42.9%.
Is CytoSorbents' 9-Day RSI too high?
CytoSorbents' current 9-Day RSI is 47.30. The Medical Devices & Instruments industry median 9-Day RSI is 41.15. CytoSorbents' value of 47.30 is 15% above this industry median. Based on the distribution chart, CytoSorbents ranks #370 out of 862 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, CytoSorbents has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does CytoSorbents' 9-Day RSI compare to LFWD and GTHP?
According to the Medical Devices & Instruments industry distribution chart, CytoSorbents ranks #370 out of 862 companies for 9-Day RSI. This puts CytoSorbents in the upper half of its industry. The industry median 9-Day RSI is 41.15. CytoSorbents' value of 47.30 is 15% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Medical Devices & Instruments company?
The median 9-Day RSI among Medical Devices & Instruments companies is 41.15, based on 862 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CytoSorbents's current 9-Day RSI of 47.30 is 15% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median 9-Day RSI is 41.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CytoSorbents's current 9-Day RSI is 47.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoSorbents stock overvalued right now?
CytoSorbents (STU:HQE) has a current 9-Day RSI of 47.30. The stock's GF Value™ is €16.19, compared to a current price of €5.92 — trading 63.4% below its estimated fair value. The current 9-Day RSI is 47.30 and 15% above the Medical Devices & Instruments industry median of 41.15. CytoSorbents' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For CytoSorbents (STU:HQE), the current 9-Day RSI is 47.30 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CytoSorbents (STU:HQE) Overvalued in 2026?
Based on GuruFocus' analysis, CytoSorbents stock appears to be undervalued.
The current stock price of €5.92 is trading 63.4% below its estimated GF Value™ of €16.19.
Key valuation signals for STU:HQE:
9-Day RSI: 47.30
GF Value™: €16.19 vs. price of €5.92 (63.4% below fair value)
Industry Position: 15% above the Medical Devices & Instruments median (#370 of 862)
No single metric tells the full story. See the STU:HQE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
45GF Score
Get the complete analysis for STU:HQE
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:HQE has been successfully added to your 
